摘要
目的：分析化疗方案、肿瘤临床分期对化疗毒副作用的影响。方法：各类小儿恶性实体肿瘤８５例，化疗方案为改良ＣＣＳＧ、ＯＰＥＣ、Ｌ、ＤＤ、ＣＹＶＡＤＩＣ、ＶＡＣ、ＰＶＢ、ＰＣＶ、ＶＡＤ、ＩＲＳ－Ⅲ、ＩＣＥ＋Ａ及Ｒｏｓｅｎ方案等。以美国东部肿瘤协作组（ＥＣＯＧ）毒性分度标准进行毒性分析。结果：８１例出现了毒性反应，占９５．３％，其中出现严重毒性反应２７例，占３１．８％；毒性反应出现时间平均为１７．９±１７．３周；含有阿霉素、博莱霉素的方案以及长期化疗，较易引起重度毒性反应；临床分期对化疗的毒性耐受亦有影响；血液系统与消化系统最常受累。结论：化疗以达到３度以下的毒性反应为好，应根据患儿的反应调整剂量，做到化疗的个体化。化疗监测可以血常规和消化道反应为指标。
Objective: To study the adverseeffects of chemotherapy in children with malignant tumors. Methods: According to the ECOG standard, 85 children with various malignant tumors received chemotherapy including CCSG, OPEC, L, DD, CYVADIC, VAC, PVB, PCV, VAD, IRSⅢ, ICE+A and Rosen schemes were studied. Results: Twentyseven of the 81 cases with sideeffects were serious. The adverse effects appeared in 17.9±17.3 weeks after the beginning of chemotherapy. The effects were different to the schemes and clinical stage. The hemological and digestive disorders were remarkable during chemotherapy. A regime of Adriamycin plus Bleomycin, and longterm treatment led to severe reactions. Conclusions: The dosage of antineoplastic agents should be adjusted and individualized according to the effects of blood system and digestive system. The sideeffects should be controlled under grade 3.
出处
《中华小儿外科杂志》
CSCD
1998年第1期6-8,共3页
Chinese Journal of Pediatric Surgery
关键词
抗肿瘤药
神经母细胞瘤
肾母细胞瘤
儿童
药物疗
Antineoplastic agents, combined Antineoplastic agents/adverse effects Neuroblastoma
